An All-Oral Combination of Capecitabine and Cyclophosphamide in Patients With Metastatic Breast Cancer (MBC)
Status:
Unknown status
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the time to progression. Secondary
objectives are safety, OS and pharmacogenetic analysis. Sixty patients will be enrolled into
this study.